Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Histogen Inc. | cnat-ex322_10.htm |
| EX-32.1 - EX-32.1 - Histogen Inc. | cnat-ex321_7.htm |
| EX-31.2 - EX-31.2 - Histogen Inc. | cnat-ex312_11.htm |
| EX-31.1 - EX-31.1 - Histogen Inc. | cnat-ex311_6.htm |
| 10-Q - 10-Q - Histogen Inc. | cnat-10q_20170930.htm |
EXHIBIT 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the reference to our firm under the caption “Experts” in the Registration Statement (Form S-3 No. 333-220014) and related Prospectus of Conatus Pharmaceuticals Inc. dated August 17, 2017 for the registration of up to $100,000,000 in aggregate principal amount of its common stock, preferred stock, debt securities, warrants and/or units and to the incorporation by reference therein of our report dated March 16, 2017, with respect to the financial statements of Conatus Pharmaceuticals Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2016, filed with the Securities and Exchange Commission.
/s/ Ernst & Young LLP
San Diego, California
November 2, 2017